Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
CAR T-Cell Therapy: Can We Afford the Cure?
By
Meg Barbor, MPH
Value-Based Care
,
Economics & Value
December 2018, Vol 9, No 4
Chicago, IL—So far, 2 chimeric antigen receptor (CAR) T-cell therapies have been approved by the FDA for some types of relapsed or refractory lymphoma and leukemia. Although CAR T-cell therapy has shown promise in many patients who have run out of standard treatment options, it is incredibly resource-intense: the complexities of its administration require an interdisciplinary approach for success, the side effects can be severe, and its high cost can reach upward of $1 million per course of treatment.
Read Article
Addressing Financial Toxicity Through Systematic Change
By
Meg Barbor, MPH
Value-Based Care
,
Economics & Value
December 2018, Vol 9, No 4
Although the cost of care can have severe effects on patients with cancer and their families, oncologists rarely address financial toxicity, according to Hanna K. Sanoff, MD, MPH, Medical Director, University of North Carolina (UNC) NC Cancer Hospital Clinics.
Read Article
Do No Financial Harm: How to Improve Cost Transparency in Cancer Care
Economics & Value
,
Value-Based Care
December 2018, Vol 9, No 4
Read Article
Cost of Treating Colorectal Cancer in the United States Double That of Canada, with No Survival Benefitc
By
Phoebe Starr
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Healthcare costs in the United States have spiraled out of control, and polls show that single-payer healthcare is gaining traction.
Read Article
PARP Inhibitors Least Cost-Effective as Maintenance Therapy in Advanced Ovarian Cancer
By
Chase Doyle
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Next-Generation Sequencing More Cost-Effective and Faster Than Single-Gene Testing
By
Phoebe Starr
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“NGS decreased the cost of testing, identified the highest percentage of targetable genetic alterations, and had the fastest turnaround,” reported Nathan A. Pennell, MD, PhD.
Read Article
Discussing Costs with Your Patient Can Reduce Financial Toxicity
By
Chase Doyle
Economics & Value
,
Financial Toxicity
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“Treating financial toxicity at the patient level is similar to treating a symptom like fatigue. You can try to prevent it, but to some degree, patients are going to experience it, and when they do, you need a plan,” says Yousuf Zafar, MD, MHS.
Read Article
Acute Myeloid Leukemia Treatment Episodes Linked to Significant Economic Burden
By
Chase Doyle
Economics & Value
,
Value-Based Care
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A retrospective analysis of a large commercial payer database has demonstrated a link between various treatment episodes of acute myeloid leukemia and substantial economic burden. According to data presented at ASH 2017, healthcare resource use and direct healthcare costs were associated with high-intensity chemotherapy induction, hematopoietic stem-cell transplantation (HSCT), and episodes of relapsed or refractory disease in a US commercially insured population.
Read Article
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Economics & Value
,
Multiple Myeloma
,
Value-Based Care
,
Hematologic Malignancies
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A recent analysis of a commercial claims database suggests that oral therapy for multiple myeloma may help decrease the economic burden for patients and healthcare systems. According to data presented at ASH 2017, patients with multiple myeloma who received injectable therapy used significantly more disability benefits and incurred higher productivity costs than patients who received oral medications.
Read Article
Overcoming Barriers to Cost Transparency in Cancer Care
By
Chase Doyle
Economics & Value
,
Value-Based Care
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Read Article
Page 2 of 18
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma